Evaluation of CAR-T cell cytotoxicity against a prostate carcinoma model

Abstract

In recent years, a new promising application of adoptive cell therapy (ACT) has been enabled by the development of technologies and the successful clinical use of T cells with a chimeric antigen receptor (CAR-T) for treating patients with malignant B-cell neoplasms. In this study, we obtained CAR-T cells with the second-generation chimeric antigen receptor FMC63-28Z-CAR. The effectiveness of the obtained CAR-T cells against the monolayer of the modified PC-3M prostate carcinoma cell line (Kat+CD19+) was evaluated. A correlation was demonstrated between an increased secretion of the proinflammatory cytokines IFNγ, TNFα, IL6 and a decreased confluence of the tumor cells monolayer. At the same time, a pronounced antitumor effect of CAR-T cells was observed starting from day 5 of coincubation. Thus, the proposed approach can potentially be applied for a preliminary evaluation of the effectiveness of biomedical CAR-T cell products in the treatment of solid tumors.

Keywords

• car-t cells
• chimeric antigen receptor
• solid tumor
• cell model
• prostate carcinoma
• pc-3m